Literature DB >> 26516422

Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation.

Jing Huang1, John H Wolk1, Michael H Gewitz1, James E Loyd1, James West1, Eric D Austin1, Rajamma Mathew1.   

Abstract

AIM: To study the genesis of neointima formation in pulmonary hypertension (PH), we investigated the role of caveolin-1 and related proteins.
METHODS: Male Sprague Dawley rats were given monocrotaline (M, 40 mg/kg) or subjected to hypobaric hypoxia (H) to induce PH. Another group was given M and subjected to H to accelerate the disease process (M + H). Right ventricular systolic pressure, right ventricular hypertrophy, lung histology for medial hypertrophy and the presence of neointimal lesions were examined at 2 and 4 wk. The expression of caveolin-1 and its regulatory protein peroxisome proliferator-activated receptor (PPAR) γ, caveolin-2, proliferative and anti-apoptotic factors (PY-STAT3, p-Erk, Bcl-xL), endothelial nitric oxide synthase (eNOS) and heat shock protein (HSP) 90 in the lungs were analyzed, and the results from M + H group were compared with the controls, M and H groups. Double immunofluorescence technique was used to identify the localization of caveolin-1 in pulmonary arteries in rat lungs and in human PH lung tissue.
RESULTS: In the M + H group, PH was more severe compared with M or H group. In the 4 wk M+H group, several arteries with reduced caveolin-1 expression in endothelial layer coupled with an increased expression in smooth muscle cells (SMC), exhibited neointimal lesions. Neointima was present only in the arteries exhibiting enhanced caveolin-1 expression in SMC. Lung tissue obtained from patients with PH also revealed neointimal lesions only in the arteries exhibiting endothelial caveolin-1 loss accompanied by an increased caveolin-1 expression in SMC. Reduction in eNOS and HSP90 expression was present in the M groups (2 and 4 wk), but not in the M + H groups. In both M groups and in the M + H group at 2 wk, endothelial caveolin-1 loss was accompanied by an increase in PPARγ expression. In the M + H group at 4 wk, increase in caveolin-1 expression was accompanied by a reduction in the PPARγ expression. In the H group, there was neither a loss of endothelial caveolin-1, eNOS or HSP90, nor an increase in SMC caveolin-1 expression; or any alteration in PPARγ expression. Proliferative pathways were activated in all experimental groups.
CONCLUSION: Enhanced caveolin-1 expression in SMC follows extensive endothelial caveolin-1 loss with subsequent neointima formation. Increased caveolin-1 expression in SMC, thus, may be a prelude to neointima formation.

Entities:  

Keywords:  Endothelial cells; Neointima; Pulmonary hypertension; Smooth muscle cells

Year:  2015        PMID: 26516422      PMCID: PMC4620079          DOI: 10.4330/wjc.v7.i10.671

Source DB:  PubMed          Journal:  World J Cardiol


  54 in total

Review 1.  Caveolins: structure and function in signal transduction.

Authors:  Wanda M Krajewska; Izabela Masłowska
Journal:  Cell Mol Biol Lett       Date:  2004       Impact factor: 5.787

2.  Suppression of eNOS-derived superoxide by caveolin-1: a biopterin-dependent mechanism.

Authors:  Kanchana Karuppiah; Lawrence J Druhan; Chun-an Chen; Travis Smith; Jay L Zweier; William C Sessa; Arturo J Cardounel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

3.  Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment.

Authors:  Danny Jonigk; Heiko Golpon; Clemens L Bockmeyer; Lavinia Maegel; Marius M Hoeper; Jens Gottlieb; Nils Nickel; Kais Hussein; Ulrich Maus; Ulrich Lehmann; Sabina Janciauskiene; Tobias Welte; Axel Haverich; Johanna Rische; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-05-11       Impact factor: 4.307

4.  Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.

Authors:  M Wang; S C Wise; T Leff; T Z Su
Journal:  Diabetes       Date:  1999-02       Impact factor: 9.461

5.  Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

Authors:  Laimute Taraseviciene-Stewart; Robertas Scerbavicius; Kang-Hyeon Choe; Carlyne Cool; Kathy Wood; Rubin M Tuder; Nana Burns; Michael Kasper; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-05-12       Impact factor: 5.464

6.  Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension.

Authors:  Jing Huang; John H Wolk; Michael H Gewitz; Rajamma Mathew
Journal:  Exp Lung Res       Date:  2010-02       Impact factor: 2.459

7.  Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.

Authors:  Gemma Llaverias; Manuel Vázquez-Carrera; Rosa M Sánchez; Véronique Noé; Carlos J Ciudad; Juan C Laguna; Marta Alegret
Journal:  J Lipid Res       Date:  2004-08-16       Impact factor: 5.922

8.  Oxidative stress in severe pulmonary hypertension.

Authors:  Rebecca Bowers; Carlyne Cool; Robert C Murphy; Rubin M Tuder; Matthew W Hopken; Sonia C Flores; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2003-12-30       Impact factor: 21.405

9.  Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension.

Authors:  Jing Huang; Pawel M Kaminski; John G Edwards; Albert Yeh; Michael S Wolin; William H Frishman; Michael H Gewitz; Rajamma Mathew
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-04       Impact factor: 5.464

Review 10.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

View more
  4 in total

1.  Pharmacological activation of PPARγ inhibits hypoxia-induced proliferation through a caveolin-1-targeted and -dependent mechanism in PASMCs.

Authors:  Kai Yang; Mingming Zhao; Junyi Huang; Chenting Zhang; Qiuyu Zheng; Yuqin Chen; Haiyang Jiang; Wenju Lu; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2018-01-03       Impact factor: 4.249

2.  Altered Lipid Domains Facilitate Enhanced Pulmonary Vasoconstriction after Chronic Hypoxia.

Authors:  Charles E Norton; Laura Weise-Cross; Rosstin Ahmadian; Simin Yan; Nikki L Jernigan; Michael L Paffett; Jay S Naik; Benjimen R Walker; Thomas C Resta
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

3.  Pulmonary Hypertension Remodels the Genomic Fabrics of Major Functional Pathways.

Authors:  Rajamma Mathew; Jing Huang; Sanda Iacobas; Dumitru A Iacobas
Journal:  Genes (Basel)       Date:  2020-01-23       Impact factor: 4.096

Review 4.  Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension.

Authors:  Rajamma Mathew
Journal:  Med Sci (Basel)       Date:  2021-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.